News
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a thr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback